Announcements
- Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
- Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
- Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources Humaines
- Transgene annonce ses prochaines rencontres avec les investisseurs
- Transgene Announces Upcoming Investor Meetings
- Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024
- Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
- Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050
- Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
More ▼
Key statistics
On Thursday, Transgene SA (TRNG:DEU) closed at 1.16, 16.82% above the 52 week low of 0.993 set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.09 |
---|---|
High | 1.19 |
Low | 1.07 |
Bid | 1.10 |
Offer | 1.22 |
Previous close | 1.08 |
Average volume | 555.00 |
---|---|
Shares outstanding | 100.85m |
Free float | 35.31m |
P/E (TTM) | -- |
Market cap | 114.97m EUR |
EPS (TTM) | -0.22 EUR |
Data delayed at least 15 minutes, as of Mar 28 2024 15:14 BST.
More ▼